Relationship of RS4646 polymorphism in CYP19A1 gene to the efficacy of hormone therapy in early breast cancer.

• DOI: 10.1200/jco.2015.33.15_suppl.e11516
• Publication Date: 2019-03-07T17:07:51Z
• Authors: Xiying Shao; Yabing Zheng; Lei Shi; Yuan Huang; Yuheng Ding; Yong Guo; Xiaojia Wang
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

e11516 Background: Polymorphisms in the aromatase CYP19A1 gene have been shown to alter aromatase activity as well as circulating steroid hormone levels in postmenopausal women. The aim was to verify the potential association between CYP19A1 genetic polymorphisms and clinical outcome of hormone therapy in hormone receptor (HR) - positive early breast cancer. Methods: Genotyping for CYP19A1 rs4646 (C/A) polymorphism was performed on 287 Chinese women with HR-positive early breast cancer in Zhejiang Cancer Hospital. Associations were evaluated between CYP19A1 rs4646 genotypes and disease-free survival (DFS). Results: Overall, women with the minor allele (AA or AC) had an improved DFS when compared with those carrying the homozygous common allele (CC) (62.7 months versus 55.6 months; HR, 0.745; 95% CI, 0.562-0.988; p = 0.04). The difference was further demonstrated by multivariate analyses (HR, 0.681; 95 % CI, 0.506-0.917; p = 0.011). In premenopausal women, AA genotype was associated with a prolonged DFS (9...